Skip to content
Study details
Enrolling now

Remimazolam NeuroImaging Trial

Keith M Vogt
NCT IDNCT07290205ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

60

Study length

about 1.8 years

Ages

18–59

Locations

1 site in PA

About this study

Researchers are testing the effects of remimazolam on brain activity and connectivity. Participants will undergo functional MRI scans while at rest, during nerve stimulation, and when learning new memories. The trial will last for 641 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Remimazolam
  • 2.Use Peripheral Nerve Stimulation
PhaseEARLY_Phase 1
DrugRemimazolam
Routeinjection
Primary goalsubjective pain ratings

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

remimazolam

Drug routes

injection, intravenous

Endpoints

Primary: subjective pain ratings

Secondary: functional magnetic resonance imaging activation of memory encoding task, functional magnetic resonance imaging activation of the response to noxious stimulation

Devices

therapeutic